Literature DB >> 9160313

Increased hepatic iron in the acquired immunodeficiency syndrome: an autopsy study.

B al-Khafaji1, S Kralovic, R D Smith.   

Abstract

Abnormalities in iron metabolism have been reported in patients with acquired immunodeficiency syndrome (AIDS). To assess the frequency of abnormal hepatic iron deposition in these patients and to examine potential causes of iron overload, we analyzed the amount of iron at different cellular sites in liver sections obtained at autopsy of 78 patients with AIDS. Quantitation of serum iron and transferrin levels and estimation of total iron binding capacity was obtained using serum from 63 patients. The number of whole blood/packed red blood cell transfusions and opportunistic infections was recorded. Of the 78 patients, 25 (32%) showed a Grade 3 or 4 (0-4 scale) iron level, distributed in three patterns, i.e., in hepatocytes only, in hepatocytes and Kupffer cells, and in Kupffer cells only. In these 25 livers, 4 had cirrhosis, with no documented cause; the mean number of transfusions was 12.5; and 16 (64%) had Mycobacterium avium-Mycobacterium intracellulare infection. In the 53 livers with little or no iron, 5 had cirrhosis, with 3 of those 5 listing alcoholic liver disease or hepatitis as the cause; the mean number of transfusions was 1.4; and 18 (34%) had Mycobacterium avium-Mycobacterium intracellulare infection. Transferrin saturation was more than 50% in 6 (29%) of 21 cases with increased hepatic iron levels and in 6 (14%) of 42 cases with little or no hepatic iron. These results indicate that hepatic iron overload in patients with AIDS is associated with blood transfusions, an elevated transferrin saturation, and Mycobacterium avium-Mycobacterium intracellulare infection. Significant hepatic iron deposition in patients with AIDS with no other apparent cause of cirrhosis suggests an etiologic role for iron in hepatic injury. The increase in hepatic iron levels in these patients has potentially adverse clinical effects related to the use of transfusions, iron supplements, and iron-containing drugs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9160313

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  2 in total

1.  Anemia, Iron Status, and HIV: A Systematic Review of the Evidence.

Authors:  Ajibola I Abioye; Christopher T Andersen; Christopher R Sudfeld; Wafaie W Fawzi
Journal:  Adv Nutr       Date:  2020-09-01       Impact factor: 8.701

2.  Insights on the relationship between structure vs. toxicological activity of antibacterial rhodamine-labelled 3-hydroxy-4-pyridinone iron(III) chelators in HepG2 cells.

Authors:  Tânia Moniz; Diana Dias da Silva; Helena Carmo; Baltazar de Castro; Maria de Lourdes Bastos; Maria Rangel
Journal:  Interdiscip Toxicol       Date:  2019-10-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.